๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Immunotherapy

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. NCT06481592Phase 212 sites๐Ÿ“ Phoenix๐Ÿ“ Los Angeles๐Ÿ“ Orlando Iovance Biotherapeutics, Inc. ยท Tests: Lifileucel Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer NCT06451211Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Tislelizumab, Oxaliplatin, S-1, Capecitabine Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC NCT06876753n/a2 sites๐Ÿ“ Nanjing๐Ÿ“ Nanjing Zhongda Hospital Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC) NCT07055399Phase 21 site๐Ÿ“ Fuzhou Fujian Cancer Hospital ยท Tests: neoadjuvant chemo-immunotherapy: Iparomlimab and tuvonralimab plus cisplatin,nab-paclitaxel for 1 cycle and Iparomlimabโ€ฆ Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) NCT07120698Phase 22 sites๐Ÿ“ Guangzhou๐Ÿ“ Chengdu Guangdong Association of Clinical Trials ยท Tests: Sintilimab Molecular Imaging of FAP Expressing Cancer-associated Fibroblasts in NSCLC Treated With Immune-checkpoint Inhibitors NCT06107608NA1 site๐Ÿ“ Brussels Jules Bordet Institute ยท Tests: FAPI PET/CT MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer NCT07894458NA1 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: Adaptive therapy of de-escalation and escalation based on MRD testing and pathological response Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy NCT06450106Phase 14 sites๐Ÿ“ Tucson๐Ÿ“ Gainesville๐Ÿ“ Melbourne N. SURGE Therapeutics ยท Tests: STM-416p Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma NCT07832006Phase 21 site๐Ÿ“ Beijing Shunda Du ยท Tests: Irreversible Electroporation, Lenvatinib, Sintilimab Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT NCT06061848Phase 2, Phase 33 sites๐Ÿ“ Lund๐Ÿ“ ร–rebro๐Ÿ“ Stockholm Lars Olaf Cardell ยท Tests: SLIT Grazax ALK Nordic 75 000 SQ-T, ILIT + Vitamin D, ILIT + placebo TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC NCT07658833n/a1 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: TACE (transarterial chemoembolization) combined with targeted/immunotherapy Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer NCT06926179n/a4 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Hohhot Peking University Cancer Hospital & Institute ยท Tests: neoadjuvant immunotherapy The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer. NCT06601010n/a1 site๐Ÿ“ Shanghai Ruijin Hospital Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC NCT07500220Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide Pathway to Peanut Tolerance NCT07592780NA1 site๐Ÿ“ Hong Kong Chinese University of Hong Kong ยท Tests: Peanut Oral Immunotherapy (OIT) Personalized Neoantigen Peptide Vaccines for Solid Tumors NCT07002203Phase 1, Phase 21 site๐Ÿ“ Bangkok Seqker Biosciences, Inc. ยท Tests: Personalized Neoantigen Peptide Vaccine Adebrelimab ยฑInduction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC NCT06510660Phase 21 site๐Ÿ“ Fuzhou Fujian Medical University Union Hospital ยท Tests: adebrelimab Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer NCT06527898Phase 1, Phase 21 site๐Ÿ“ Hefei Anhui Provincial Hospital ยท Tests: hypofractionated radiotherapy with immunotherapy Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie NCT06031233Phase 41 site๐Ÿ“ Zwolle Isala ยท Tests: Nivolumab, Pembrolizumab, Ipilimumab, Durvalumab, Atezolizumab Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC NCT06878274Phase 21 site๐Ÿ“ Montreal Centre hospitalier de l'Universitรฉ de Montrรฉal (CHUM) ยท Tests: Post-operative radiotherapy Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia NCT07422779NA1 site๐Ÿ“ Ljubljana Institute of Oncology Ljubljana ยท Tests: Pembrolizumab, Nivolumab, Ipilimumab Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) NCT07572136Phase 11 site๐Ÿ“ Bethesda National Cancer Institute (NCI) ยท Tests: TSLPR-CART, Cyclophosphamide, Fludarabine Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer NCT07174570Phase 24 sites๐Ÿ“ Atlanta๐Ÿ“ Atlanta๐Ÿ“ Atlanta Emory University ยท Tests: Celecoxib, Durvalumab, Tremelimumab, Biospecimen Collection, Computed Tomography Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma NCT06755567n/a1 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: MRI-based radiomics-clinical model MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma NCT07106736Phase 21 site๐Ÿ“ Tianjin Institute of Hematology & Blood Diseases Hospital, China ยท Tests: BCMA CAR-T, GPRC5D/CD3 BiTEs The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer. NCT06851299Phase 21 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: trop2-ADC, ADC +anti-angiogenic drug, ADC + PD1 monoclonal antibody +anti-angiogenic drug GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFฮฒ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers NCT03198052Phase 12 sites๐Ÿ“ Guangzhou๐Ÿ“ Guangzhou Second Affiliated Hospital of Guangzhou Medical University ยท Tests: CAR-T cells targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGFฮฒ, HER2, Lewis-Y, AXL, or EGFR A Study of GC101 TIL in Advanced Breast Cancer (10hospital) NCT05142475EARLY Phase 11 site๐Ÿ“ Shanghai Shanghai Juncell Therapeutics ยท Tests: Tumor Infiltrating Lymphocytes (TIL) Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy NCT07354100Phase 1, Phase 21 site๐Ÿ“ Chicago University of Chicago ยท Tests: Lactulose Immune Profiling for Cancer Immunotherapy Response NCT06116032n/a1 site๐Ÿ“ Lebanon Dartmouth-Hitchcock Medical Center ยท Tests: Methylation Cytometry
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy